NABL vs. CLBT, LSPD, MQ, INST, AVPT, MTTR, COUR, CXM, MLNK, and AMPL
Should you be buying N-able stock or one of its competitors? The main competitors of N-able include Cellebrite DI (CLBT), Lightspeed Commerce (LSPD), Marqeta (MQ), Instructure (INST), AvePoint (AVPT), Matterport (MTTR), Coursera (COUR), Sprinklr (CXM), MeridianLink (MLNK), and Amplitude (AMPL). These companies are all part of the "prepackaged software" industry.
Cellebrite DI (NASDAQ:CLBT) and N-able (NYSE:NABL) are both mid-cap business services companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.
N-able has a net margin of 6.27% compared to N-able's net margin of -24.94%. N-able's return on equity of 173.14% beat Cellebrite DI's return on equity.
Cellebrite DI received 6 more outperform votes than N-able when rated by MarketBeat users. However, 63.33% of users gave N-able an outperform vote while only 53.19% of users gave Cellebrite DI an outperform vote.
In the previous week, N-able had 2 more articles in the media than Cellebrite DI. MarketBeat recorded 6 mentions for N-able and 4 mentions for Cellebrite DI. N-able's average media sentiment score of 0.89 beat Cellebrite DI's score of 0.18 indicating that Cellebrite DI is being referred to more favorably in the media.
45.9% of Cellebrite DI shares are owned by institutional investors. Comparatively, 96.4% of N-able shares are owned by institutional investors. 5.7% of Cellebrite DI shares are owned by insiders. Comparatively, 1.4% of N-able shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
N-able has higher revenue and earnings than Cellebrite DI. Cellebrite DI is trading at a lower price-to-earnings ratio than N-able, indicating that it is currently the more affordable of the two stocks.
Cellebrite DI presently has a consensus target price of $12.42, suggesting a potential upside of 7.69%. N-able has a consensus target price of $15.50, suggesting a potential upside of 21.28%. Given Cellebrite DI's higher probable upside, analysts plainly believe N-able is more favorable than Cellebrite DI.
Cellebrite DI has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, N-able has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.
Summary
Cellebrite DI and N-able tied by winning 9 of the 18 factors compared between the two stocks.
Get N-able News Delivered to You Automatically
Sign up to receive the latest news and ratings for NABL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NABL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
